» Articles » PMID: 30674567

Predictive Risk Factors of Acute Kidney Injury After Cytoreductive Surgery and Cisplatin-based Hyperthermic Intra-peritoneal Chemotherapy for Ovarian Peritoneal Carcinomatosis

Overview
Date 2019 Jan 25
PMID 30674567
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of our study was to assess the incidence and identify the predictive risk factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy.

Methods: This is a retrospective study from two centers evaluating patients with advanced or recurrent ovarian cancer who underwent cytoreductive surgery followed by cisplatin-based hyperthermic intra-peritoneal chemotherapy from January 2007 to December 2013. Patients were classified into two groups according to the occurrence of acute kidney injury, defined as a glomerular filtration rate at post-operative day 7 25% lower than at day 0. We also evaluated acute kidney injury following Risk, Injury, Failure, Lost and End-stage kidney function criteria. Univariate and multivariate analyses were conducted in order to assess the association between different variables and the occurrence of acute kidney injury.

Results: Sixty-six patients were included: 29 (44%) underwent first-line treatment and 37 (56%) were treated for recurrent disease. The incidence of post-operative acute kidney injury was 48%. After multivariate analysis, hypertension (OR 18.6; 95% CI 1.9 to 182.3; p=0.012) and low intra-operative diuresis (OR 0.5; 95% CI 0.4 to 0.8; p=0.001) were associated with acute kidney injury.

Conclusion: The incidence of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy was high. Hypertension and low intra-operative diuresis were independent risk factors for this complication. Adequate peri-operative hydration, in order to maintain correct diuresis, could decrease the occurrence of acute kidney injury in patients undergoing cytoreductive surgery plus hyperthermic intra-peritoneal chemotherapy.

Citing Articles

Cytoreductive Surgery Plus HIPEC in Recurrent or Newly Diagnosed Advanced Epithelial Ovarian Cancer: a Meta-analysis.

Taliento C, Restaino S, Arcieri M, Scutiero G, Greco P, Scambia G Ann Surg Oncol. 2025; .

PMID: 39904852 DOI: 10.1245/s10434-025-16979-6.


Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice.

Zhou Q, Harding J, Fan P, Spasojevic I, Kovacs A, Akk A Nanomaterials (Basel). 2024; 14(21.

PMID: 39513832 PMC: 11547995. DOI: 10.3390/nano14211752.


Intraoperative hyperthermia is associated with increased acute kidney injury following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cohort study.

Gao S, Ma J, Kong H, Ma R, Chen S, Wang D Ren Fail. 2024; 46(2):2420835.

PMID: 39494507 PMC: 11536636. DOI: 10.1080/0886022X.2024.2420835.


Side-Effects on the Renal function of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Beltran D, Pintado M, Onoro A, Unzue I, Sanz R, Alonso M Int J Med Sci. 2024; 21(13):2537-2543.

PMID: 39439460 PMC: 11492877. DOI: 10.7150/ijms.97774.


Nephrotoxicity Associated with Cytoreductive Surgery Combined with Cisplatin-Based Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignant Disease: A Systematic Review and Meta-Analysis.

Grillo-Marin C, Anton-Rodriguez C, Prieto L, Ortega-Perez G, Gonzalez-Moreno S J Clin Med. 2024; 13(13).

PMID: 38999359 PMC: 11242517. DOI: 10.3390/jcm13133793.